

Original Article

Prognostic factors of premature closure of the ductus arteriosus in utero: a systematic literature review

Hidekazu Ishida,^{1,2} Yukiko Kawazu,² Futoshi Kayatani,² Noboru Inamura²

¹*Department of Pediatrics, Osaka University Graduate School of Medicine;* ²*Pediatric Cardiology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan*

Abstract Background: A number of case reports show various outcomes of premature closure of the ductus arteriosus in utero, including persistent pulmonary hypertension of the newborn and fetal or neonatal death; however, no study clarifies the clinical observations that are related to their prognoses. We aimed to clarify the prognostic factors of intrauterine ductal closure by a systematic literature review. **Data sources:** We searched PubMed database (1975–2014) to identify case reports and studies on intrauterine closure of the ductus arteriosus, including maternal, fetal, and neonatal clinical information and their prognoses. **Results:** We analysed the data of 116 patients from 39 articles. Of these, 12 (10.3%) died after birth or in utero. Fetal or neonatal death was significantly correlated with fetal hydrops (odds ratio = 39.6, 95% confidence interval = 4.6–47.8) and complete closure of the ductus arteriosus (odds ratio = 5.5, 95% confidence interval = 1.2–15.1). Persistent pulmonary hypertension was observed in 33 cases (28.4%), and was also correlated with fetal hydrops (odds ratio = 4.2, 95% confidence interval = 1.3–4.6) and complete closure of the ductus arteriosus (odds ratio = 5.5, 95% confidence interval = 1.6–6.0). Interestingly, maternal drug administration was not correlated with the risk of death and persistent pulmonary hypertension. **Conclusions:** Fetal hydrops and complete ductal closure are significant risk factors for both death and persistent pulmonary hypertension. Cardiac or neurological prognoses could be favourable if the patients overcome right heart failure during the perinatal period.

Keywords: Ductus arteriosus; intrauterine closure; persistent pulmonary hypertension; fetal hydrops; prognosis

Received: 14 March 2016; Accepted: 16 May 2016; First published online: 20 June 2016

THE DUCTUS ARTERIOSUS IS CRITICAL FOR NORMAL fetal circulation. It can lead ~75% of right ventricular output from the pulmonary artery to the aorta.¹ The main factors maintaining patency of the ductus arteriosus in utero are high levels of circulating prostaglandin E₂ and locally produced prostaglandin E₁.² Therefore, it has been widely recognised that maternal administration of prostaglandin synthase inhibitors such as non-steroidal anti-inflammatory drugs and corticosteroids could be associated with an increased risk of prenatal closure of

the ductus arteriosus.³ Recently, it has been reported that maternal intake of polyphenol-rich foods such as green tea, mate tea, dark chocolate, and grape juice could be a risk factor for intrauterine ductal constriction.⁴ The closure of the ductus arteriosus causes elevation of right ventricular afterload, and it finally results in right heart failure and death.⁵ In contrast, it can also cause volume overload of the pulmonary circulation in fetuses, resulting in persistent pulmonary hypertension in the newborn.⁶

Although a considerable number of case reports on intrauterine constriction or closure of the ductus arteriosus are available, the mortality, prognoses, and prognostic factors are not fully understood. It is very important to realise what kinds of clinical findings such as fetal echocardiographic parameters could

Correspondence to: H. Ishida, Department of Pediatrics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Tel: +816 6879 3932; Fax: +816 6879 3939; E-mail: hideishi@ped.med.osaka-u.ac.jp

affect the prognosis of intrauterine ductal closure, as it can facilitate us in deciding the appropriate timing of delivery after diagnosis. Therefore, in this study, we aimed to clarify the prognostic factors of premature closure of the ductus arteriosus in utero by undertaking a systematic literature review.

Materials and methods

A comprehensive search for studies and case reports on premature constriction or closure of the ductus arteriosus was conducted using PubMed database (from 1975 to 2014). The search was conducted using the following keywords: (“ductus arteriosus” AND “closure” NOT “patent”) or (“ductus arteriosus” AND “constriction” NOT “patent”). The search was limited to human studies published in English. From the literature, we selected relevant studies including fetal and neonatal clinical information and their prognoses, and excluded cases with other CHD – for example, transposition of the great arteries – and congenital systemic anomalies – for example, chromosomal abnormalities. We then extracted data from all the articles, including maternal age, maternal drug history, types of the drugs used, gestational age of diagnosis and birth, fetal echocardiographic findings, presence of fetal hydrops, birth weight, persistent pulmonary hypertension after birth, and their cardiac and neurological outcomes.

We divided the patients into the following three groups: good prognosis without any complication, fetal or neonatal death, and persistent pulmonary hypertension in the newborn. First, we compared the mothers' age, gestational age at diagnosis, gestational age at birth, and birth weight in each group. Next, we analysed the following prognostic factors by calculating odds ratio and 95% confidential intervals: fetal hydrops, maternal drug administration, and fetal echocardiographic findings including right heart dilatation, tricuspid regurgitation, and complete closure of the ductus arteriosus. Values are expressed as mean \pm standard deviation. Statistical significance was defined at $p < 0.05$. StatView version 5.0 software was used for statistical analyses.

Results

The electronic search yielded a total of 243 articles, of which 39 – including 116 patients – were reports on intrauterine closure and constriction of the ductus arteriosus, containing fetal and maternal clinical information and prognoses.^{5–43} The mean age of the mothers was 29.5 ± 4.5 years. The mean gestational age at diagnosis was 32.2 ± 3.8 weeks, although six patients were diagnosed after birth. The mean gestational age at birth was 37.1 ± 3.5 weeks, and the

Table 1. Clinical characteristics of the cases (mean \pm standard deviation).

	All (n = 116)	Good (n = 71)	Death (n = 12)	PPHN (n = 33)
Age of mothers (year)	29.5 \pm 4.5	29.9 \pm 4.0	32.5 \pm 5.2	28.6 \pm 4.2
GA at diagnosis (week)	32.2 \pm 3.8	32.5 \pm 3.7	30.6 \pm 3.0	35.0 \pm 3.7
GA at birth (week)	37.1 \pm 3.5	37.9 \pm 3.3	33.9 \pm 3.5	37.5 \pm 3.0
Birth weight (kg)	2.6 \pm 0.8	2.5 \pm 0.8	2.4 \pm 1.0	3.1 \pm 0.5

GA = gestational age; PPHN = persistent pulmonary hypertension of the newborn

mean birth weight was 2.6 ± 0.8 kg. These clinical data were not significantly different among each prognosis – namely, good, death, and persistent pulmonary hypertension of the newborn (Table 1).

Of the 116 cases, 71 mothers (62.8%) had received non-steroidal, anti-inflammatory drugs and/or corticosteroids. The anti-inflammatory drugs included indomethacin (42 cases), nimesulide (10 cases), diclofenac (four cases), and aspirin (two cases). We found no association between the type of drug and the incidence of death or persistent pulmonary hypertension.

In 86 patients, fetal echocardiographic findings were available for fetal right heart dilatation and tricuspid regurgitation; 60 patients (70.0%) had right heart dilatation, and 67 patients (77.9%) had tricuspid regurgitation. Complete closure of the ductus arteriosus was diagnosed in 19 cases (20.2%) by fetal echocardiography or from autopsy findings of stillborn babies. Fetal hydrops was observed in 22 cases (19.0%) either by fetal echocardiography or by diagnosis at birth.

Table 2 shows the summary of analyses for all groups; eight neonates (7.0%) died after birth – all within 3 days – despite intensive treatments for pulmonary hypertension and right heart failure. Moreover, four fetuses (3.4%) died in utero between 29 and 33 weeks of gestation. In all cases of intrauterine death, fetal hydrops was observed. Of the 22 hydropic fetuses, 12 (54.5%) died in utero or after birth. Fisher's exact test demonstrated that fetal or neonatal death was significantly correlated with fetal hydrops ($p < 0.001$), but not with maternal drug administration ($p = 0.066$). The odds ratio of fetal hydrops in death was 39.6, with a 95% confidence interval of 4.6–47.8, as compared with good prognosis cases. The relationships between death and fetal echocardiographic findings such as right heart

Table 2. Prognostic factors for death and persistent pulmonary hypertension after intrauterine closure of the ductus arteriosus.

	All (n = 116)	Good (n = 71)	Death (n = 12) p value OR [95% CI]	PPHN (n = 33) p value OR [95% CI]
Fetal hydrops	22 (19%)	5 (7%)	9 (75%) <0.0001 39.6 [3.1–69.3]	8 (24%) 0.015 4.2 [1.3–4.6]
Maternal drug administration	71 (61%)	49 (69%)	5 (42%) 0.066 0.32 [0.13–1.10]	17 (52%) 0.245 0.48 [0.35–1.06]
Fetal right heart dilatation	79 (73%)	44 (62%)	7 (100%) NA in 5 cases 0.152 4.3 [0.5–29.7]	28 (93%) NA in 3 cases 0.0014 8.6 [1.4–22.1]
Fetal tricuspid regurgitation	85 (81%)	54 (76%)	4 (80%) NA in 7 cases 0.841 1.3 [0.15–10.4]	27 (90%) NA in 3 cases 0.108 2.8 [0.75–6.6]
Complete closure of the DA	27 (26%)	11 (15%)	4 (50%) NA in 4 cases 0.0183 5.5 [1.2–15.1]	12 (50%) NA in 9 cases 0.0017 5.5 [1.6–6.0]

CI = confidence interval; DA = ductus arteriosus; NA = not available; OR = odds ratio; PPHN = persistent pulmonary hypertension of the newborn
p value was calculated as compared with good prognosis

dilatation and tricuspid regurgitation cannot be clearly determined, which might be due to the lack of fetal echocardiographic data in several cases of death; however, the statistical analysis showed that complete closure of the ductus was significantly correlated with the risk of death ($p = 0.0183$; odds ratio 5.5, 95% confidence interval 1.2–15.1).

Persistent pulmonary hypertension of the newborn was observed in 33 cases (28.4%), 14 of which required mechanical ventilation (42.4%), including five patients who received nitric oxide inhalation. Fisher's exact tests revealed that persistent pulmonary hypertension was significantly correlated with fetal hydrops ($p = 0.015$; odds ratio 4.2, 95% confidence interval 1.3–4.6) and fetal right heart dilatation ($p = 0.0014$; odds ratio 8.6, 95% confidence interval 1.4–22.1), but not with maternal drug administration ($p = 0.245$) and fetal tricuspid regurgitation ($p = 0.108$). Although we found no information for complete closure or constriction of the ductus in nine cases in the persistent pulmonary hypertension group, the statistical analysis showed that complete ductal closure was significantly correlated with persistent pulmonary hypertension ($p = 0.0017$; odds ratio 5.5, 95% confidence interval 1.6–6.0).

Patients who could survive the perinatal period, regardless of persistent pulmonary hypertension, had no neurological or cardiac complications for at least 1–10 months; however, 11 patients (9.5%) had mild right ventricular hypertrophy or tricuspid regurgitation

without any clinical symptoms, as detected by follow-up echocardiography at 1–6 months of age.

Discussion

Premature closure of the ductus arteriosus without congenital cardiac defects has been reported by case reports. As most of the studies have focussed on maternal drug history or echocardiographic findings of fetuses, their prognoses and prognostic factors have not been clearly elucidated until now. In this study, we calculated the perinatal mortality of prenatal closure of the ductus arteriosus as 10.3%; however, as the published case reports tended to be limited to more severe cases, mortality may be lower than that indicated by our systematic review. We also found that fetal hydrops, which is usually attributed to severe right heart dysfunction, is a significant risk factor for both death and persistent pulmonary hypertension of the newborn. Notably, 40% of the hydropic fetuses died prenatally or immediately after birth, and more than half of them were affected by persistent pulmonary hypertension even if they could survive during the perinatal period. This finding suggests that hydropic fetuses should be recommended to be delivered immediately after diagnosis, and to prepare for the intensive treatments for pulmonary hypertension such as oxygen therapy, mechanical ventilation, and nitric oxide inhalation. Although there is no statistical significance, death cases tended to have an earlier gestational age at diagnosis and an earlier delivery as compared with the

surviving cases (Table 1). As immature and early fetal hearts have less compliance than fetal or postnatal hearts at later gestation,⁴⁴ earlier closure of the ductus arteriosus might evoke more severe right heart failure and fetal hydrops. We also found that the other maternal factors and fetal echocardiographic parameters, such as maternal drug administration, types of maternal drugs, fetal right heart dilatation, and fetal tricuspid regurgitation, were not significantly correlated with perinatal death. Nevertheless, in several cases of death, fetal echocardiography was not available because they were already dead at diagnosis; therefore, whether these fetal echocardiographic findings are truly unable to predict fetal or neonatal death is uncertain.

Persistent pulmonary hypertension after birth could be caused by constriction or closure of the ductus arteriosus in utero due to massive volume overload in pulmonary circulation. The constriction or closure of the ductus arteriosus causes most of the right ventricular output to be forced through the premature lungs, which results in endothelial damage and medial wall thickening of the pulmonary vessels, inhibiting the postnatal fall of pulmonary vascular resistance.⁴⁵ In this study, we estimate the incidence of persistent pulmonary hypertension of the newborn as 28.4%. It is significantly correlated with fetal hydrops, fetal right heart dilatation, and complete closure of the ductus arteriosus, but not with maternal drug administration. The severity of pulmonary hypertension seems to be extremely different among the cases – for example, some patients required mechanical ventilation and nitric oxide inhalation, whereas others required only oxygen inhalation for a couple of days. The reasons for this discrepancy are not clear, but previous animal studies have suggested that pulmonary vascular resistance after birth is correlated with the duration of closure of the ductus arteriosus.⁴⁵ Thus, the length of time from the beginning of ductal constriction until delivery might determine the severity of pulmonary hypertension. In addition, considering our fetal echocardiographic findings in the previous report,⁴² the maximum velocity of tricuspid regurgitation, which is attributed to high right ventricular pressure, may predict the severity of pulmonary hypertension. As the number of cases in that study was relatively small, we need to include a larger number of cases to confirm these results.

This study suggests that the cardiac and neurological outcomes of premature closure of the ductus arteriosus are favourable if fetuses can overcome right heart failure and persistent pulmonary hypertension during the perinatal period. In postnatal circulation, the closure of the ductus arteriosus obviously does not affect the systemic and pulmonary circulation.

Therefore, fetal right heart dysfunction could subsequently be improved after birth, which could in turn result in favourable outcomes.

Limitations

There are several limitations to this study. First, the definition of constriction and closure of the ductus arteriosus could be different among case reports. Second, the fetal echocardiographic parameters including right heart dilatation and tricuspid regurgitation were qualitatively assessed without any common criteria.

Conclusion

The prognosis of premature closure of the ductus arteriosus in utero depends predominantly on the presence of fetal hydrops and complete closure of the ductus arteriosus. Fetal hydrops and complete ductal closure are significant risk factors for both death and persistent pulmonary hypertension in the newborn. The cardiac and neurological outcomes are usually good if they can survive the perinatal period. Hydropic fetuses and/or complete closure of the ductus arteriosus should be recommended to be delivered immediately after diagnosis, and might require intensive care for pulmonary hypertension.

Acknowledgements

The authors thank Dr Shigetoyo Kogaki and Prof. Keiichi Ozono, Osaka University Graduate School of Medicine, for the useful discussions.

Authors contributions: H.I. and N.I. conducted the study and wrote the manuscript. Y.K. and F.K. contributed to the discussion of the results.

Financial Support

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

Conflicts of Interest

None.

References

1. Smith GC. The pharmacology of the ductus arteriosus. *Pharmacol Rev* 1998; 50: 35–58.
2. Coceani F, Olley PM. The response of the ductus arteriosus to prostaglandins. *Can J Physiol Pharmacol* 1973; 51: 220–225.
3. Koren G, Florescu A, Costei AM, et al. Nonsteroidal anti-inflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. *Ann Pharmacother* 2006; 40: 824–829.
4. Zielinsky P, Piccoli AL, Luiz J, et al. New insights on fetal ductal constriction: role of maternal ingestion of polyphenol-rich foods. *Expert Rev Cardiovasc Ther* 2010; 8: 291–298.

5. Kondo T, Kitazawa R, Noda-Maeda N, et al. Fetal hydrops associated with spontaneous premature closure of ductus arteriosus. *Pathol Int* 2006; 56: 554–557.
6. Siu KL, Lee WH. Maternal diclofenac sodium ingestion and severe neonatal pulmonary hypertension. *J Paediatr Child Health* 2004; 40: 152–153.
7. Mielke G, Steil E, Breuer J, et al. Circulatory changes following intrauterine closure of the ductus arteriosus in the human fetus and newborn. *Prenat Diagn* 1998; 18: 139–145.
8. Auer M, Brezinka C, Eller P, et al. Prenatal diagnosis of intrauterine premature closure of the ductus arteriosus following maternal diclofenac application. *Ultrasound Obstet Gynecol* 2004; 23: 513–516.
9. Leal SD, Cavalle-Garrido T, Ryan G, et al. Isolated ductal closure in utero diagnosed by fetal echocardiography. *Am J Perinatol* 1997; 14: 205–210.
10. Truter PJ, Franszen S, van der Merwe JV, et al. Premature closure of the ductus arteriosus causing intra-uterine death. A case report. *S Afr Med J* 1986; 70: 557–558.
11. Chao RC, Ho ES, Hsieh KS. Doppler echocardiographic diagnosis of intrauterine closure of the ductus arteriosus. *Prenat Diagn* 1993; 13: 989–994.
12. Kim HS, Sohn S, Park MY, et al. Coexistence of ductal constriction and closure of the foramen ovale in utero. *Pediatr Cardiol* 2003; 24: 588–590.
13. Mielke G, Steil E, Gonser M. Prenatal diagnosis of idiopathic stenosis of the ductus arteriosus associated with fetal atrial flutter. *Fetal Diagn Ther* 1997; 12: 46–49.
14. Talati AJ, Salim MA, Korones SB. Persistent pulmonary hypertension after maternal naproxen ingestion in a term newborn: a case report. *Am J Perinatol* 2000; 17: 69–71.
15. Soslow JH, Friedberg MK, Silverman NH. Idiopathic premature closure of the ductus arteriosus: an indication for early delivery. *Echocardiography* 2008; 25: 650–652.
16. Mushiaki K, Motoyoshi F, Kinoshita Y, et al. Severe heart failure due to ductal constriction caused by maternal indomethacin. *Pediatr Int* 2002; 44: 174–176.
17. Oyer CE, Feit LR, Rogers BB, et al. In utero development of hypertensive necrotizing pulmonary arterial lesions: report of a case associated with premature closure of the ductus arteriosus and pulmonary hypoplasia. *Cardiovasc Pathol* 2000; 9: 39–47.
18. Ben-David Y, Hallak M, Rotschild A, et al. Indomethacin and fetal ductus arteriosus: complete closure after cessation of prolonged therapeutic course. *Fetal Diagn Ther* 1996; 11: 341–344.
19. Hofstadler G, Tulzer G, Altmann R, et al. Spontaneous closure of the human fetal ductus arteriosus – a cause of fetal congestive heart failure. *Am J Obstet Gynecol* 1996; 174: 879–883.
20. Schiessl B, Schneider KT, Zimmermann A, et al. Prenatal constriction of the fetal ductus arteriosus – related to maternal pain medication? *Z Geburtshilfe Neonatol* 2005; 209: 65–68.
21. Paladini D, Marasini M, Volpe P. Severe ductal constriction in the third-trimester fetus following maternal self-medication with nimesulide. *Ultrasound Obstet Gynecol* 2005; 25: 357–361.
22. Luchese S, Manica JL, Zielinsky P. Intrauterine ductus arteriosus constriction: analysis of a historic cohort of 20 cases. *Arq Bras Cardiol* 2003; 81: 399–404.
23. Levy R, Matitiau A, Ben Arie A, et al. Indomethacin and corticosteroids: an additive constrictive effect on the fetal ductus arteriosus. *Am J Perinatol* 1999; 16: 379–383.
24. Moise KJJ, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. *N Engl J Med* 1988; 319: 327–331.
25. Prefumo F, Marasini M, De Biasio P, et al. Acute premature constriction of the ductus arteriosus after maternal self-medication with nimesulide. *Fetal Diagn Ther* 2008; 24: 35–38.
26. Tarcan A, Gurakan B, Yildirim S, et al. Persistent pulmonary hypertension in a premature newborn after 16 hours of antenatal indomethacin exposure. *J Perinat Med* 2004; 32: 98–99.
27. Pratt L, Digiosia J, Swenson JN, et al. Reversible fetal hydrops associated with indomethacin use. *Obstet Gynecol* 1997; 90: 676–678.
28. Eidem BW, MacMillan WE, Cetta F. Intermittent constriction of the ductus arteriosus in the fetus: a cause for concern? *Tex Heart Inst J* 2000; 27: 416–417.
29. Mielke G, Peukert U, Krapp M, et al. Fetal and transient neonatal right heart dilatation with severe tricuspid valve insufficiency in association with abnormally S-shaped kinking of the ductus arteriosus. *Ultrasound Obstet Gynecol* 1995; 5: 338–341.
30. Hallak M, Reiter AA, Ayres NA, et al. Indomethacin for preterm labor: fetal toxicity in a dizygotic twin gestation. *Obstet Gynecol* 1991; 78: 911–913.
31. Becker AE, Becker MJ, Wagenvoort CA. Premature contraction of the ductus arteriosus: a cause of foetal death. *J Pathol* 1977; 121: 187–191.
32. Mas C, Menahem S. Premature in utero closure of the ductus arteriosus following maternal ingestion of sodium diclofenac. *Aust N Z J Obstet Gynaecol* 1999; 39: 106–107.
33. Zenker M, Klinge J, Kruger C, et al. Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: a case report. *J Perinat Med* 1998; 26: 231–234.
34. Harlass FE, Duff P, Brady K, et al. Hydrops fetalis and premature closure of the ductus arteriosus: a review. *Obstet Gynecol Surv* 1989; 44: 541–543.
35. Trevett TN, Cotton J. Idiopathic constriction of the fetal ductus arteriosus. *Ultrasound Obstet Gynecol* 2004; 23: 517–519.
36. Mogilner BM, Ashkenazy M, Borenstein R, et al. Hydrops fetalis caused by maternal indomethacin treatment. *Acta Obstet Gynecol Scand* 1982; 61: 183–185.
37. Abman SH, Accurso FJ. Acute effects of partial compression of ductus arteriosus on fetal pulmonary circulation. *Am J Physiol* 1989; 257: H626–H634.
38. Enzensberger C, Wienhard J, Weichert J, et al. Idiopathic constriction of the fetal ductus arteriosus: three cases and review of the literature. *J Ultrasound Med* 2012; 31: 1285–1291.
39. Gregor M, Hodik K, Tošner J. Premature closure of the ductus arteriosus. *Int J Gynaecol Obstet* 2011; 114: 80.
40. Wei S, Ailu C, Ying Z, et al. Idiopathic occlusion of the fetal ductus arteriosus without lumen narrowing. *Echocardiography* 2011; 28: E85–E88.
41. Gewillig M, Brown SC, De Catte L, et al. Premature foetal closure of the arterial duct: clinical presentations and outcome. *Eur Heart J* 2009; 30: 1530–1536.
42. Ishida H, Inamura N, Kawazu Y, et al. Clinical features of the complete closure of the ductus arteriosus prenatally. *Congenit Heart Dis* 2011; 6: 51–56.
43. Hayrullah A, Zehra K, Tamer B. Transient severe isolated right ventricular hypertrophy in neonates. *J Clin Neonatol* 2014; 3: 161–163.
44. Carceller-Blanchard AM, Fouron JC. Determinants of the Doppler flow velocity profile through the mitral valve of the human fetus. *Br Heart J* 1993; 70: 457–460.
45. Morin FC, Egan EA. The effect of closing the ductus arteriosus on the pulmonary circulation of the fetal sheep. *J Dev Physiol* 1989; 11: 283–287.